BlackRock Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

BlackRock Group’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.47M	Buy	29,398 +11,531	+65%	+$606K	﹤0.01%	1943
2016 Q3	$937K	Sell	17,867 -280	-2%	-$13.4K	﹤0.01%	2067
2016 Q2	$751K	Buy	18,147 +11,290	+165%	+$491K	﹤0.01%	2097
2016 Q1	$279K	Sell	6,857 -1,733	-20%	-$59.6K	﹤0.01%	2463
2015 Q4	$357K	Sell	8,590 -8,130	-49%	-$273K	﹤0.01%	2327
2015 Q3	$257K	Sell	16,720 -11,797	-41%	-$254K	﹤0.01%	2447
2015 Q2	$708K	Buy	28,517 +11,687	+69%	+$260K	﹤0.01%	2128
2015 Q1	$385K	Buy	16,830 +4,895	+41%	+$124K	﹤0.01%	2289
2014 Q4	$322K	Buy	+11,935	New	+$205K	﹤0.01%	2377

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's FPRX Position: Q4 2016 in Review

BlackRock Group increased its Five Prime Therapeutics, Inc. (FPRX) stake by 65% in Q4 2016, buying an estimated $606K and bringing the position to 29,398 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1943.

BlackRock Group first reported a position in FPRX in Q4 2014 and has held it in 9 quarters since. 172 funds tracked by Wall St. Rank hold FPRX as of Q4 2016.

BlackRock Group held 29,398 shares of Five Prime Therapeutics, Inc. worth $1.47M as of Q4 2016.
BlackRock Group bought 11,531 Five Prime Therapeutics, Inc. shares in Q4 2016, an estimated $606K.
Five Prime Therapeutics, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1943 holding.
BlackRock Group first reported a position in Five Prime Therapeutics, Inc. in Q4 2014 and has held it in 9 quarters since.
172 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.